ent-Rivaroxaban is the R-isomer of Rivaroxaban (R538000), which is a novel antithrombotic agent. A highly potent and selective, direct FXa inhibitor.
5-r-rivaroxaban is a selective inhibitor of human factor xa with ic50 value of 0.7 nmol/l [1].factor xa is a serine endopeptidase enzyme and plays an important role in the convergence point of the intrinsic and extrinsic pathways in blood coagulation system [2].5-r-rivaroxaban is an oral, direct factor xa inhibitor and the inhibition is species-dependent. when tested with purified factoe xa from human or rabbit, 5-r-rivaroxaban showed similar affinity with ic50 value of 0.7 nmol/l and 0.8 nmol/l, respectively, while had a ic50 value as low as 3.4 nmol/l when tested with rat factor xa [1].pre-treated anaesthetised rat model with intravenous 5-r-rivaroxaban at a dose of 2 mg/kg, and after bleeding initiated intravenous treated with rfviia (100/400 μg/kg), pcc (25/50 u/kg) or apcc (50/100 u/kg), the result showed that 5-r-rivaroxaban pre-treatment significantly shorten bleeding time and clotting time compared with 5-r-rivaroxaban alone treated group [2]. similar results were obtained when tested with rabbit model [1].it has been reported that 5-r-rivaroxaban is a promising drug for atrial fibrillation, venous thromboembolism or thromboembolic disorders in clinic [3] [4] [1].
[1]. perzborn, e., et al., rivaroxaban: a new oral factor xa inhibitor. arterioscler thromb vasc biol, 2010. 30(3): p. 376-81.
[2]. perzborn, e., et al., reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. thromb haemost, 2013. 110(1): p. 162-72.
[3]. beyer-westendorf, j., et al., efficacy and safety of rivaroxaban or fondaparinux thromboprophylaxis in major orthopedic surgery: findings from the ortho-tep registry. j thromb haemost, 2012. 10(10): p. 2045-52.
[4]. palareti, g., et al., clinical management of rivaroxaban-treated patients. expert opin pharmacother, 2013. 14(5): p. 655-67.
